Nubeqa vs. Rubraca
Are Nubeqa and Rubraca the Same Thing?
Nubeqa (darolutamide) and Rubraca (rucaparib tablets) are used to treat different types of cancer.
Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients are selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
Nubeqa and Rubraca belong to different drug classes. Nubeqa is an androgen receptor inhibitor and Rubraca is a poly (ADP-ribose) polymerase (PARP) inhibitor.
Side effects of Nubeqa and Rubraca that are similar include fatigue and rash.
Side effects of Nubeqa that are different from Rubraca include pain in extremities.
Side effects of Rubraca that are different from Nubeqa include nausea, vomiting, anemia, abdominal pain, changes in taste, constipation, decreased appetite, diarrhea, low levels of platelets in the blood (thrombocytopenia), shortness of breath, dizziness, low levels of white blood cells (neutropenia), fever, skin sensitivity to sunlight, and itching.
Nubeqa may interact with rifampicin, itraconazole, midazolam, and rosuvastatin.
Rubraca may interact with other drugs.
What Are Possible Side Effects of Nubeqa?
Common side effects of Nubeqa include:
- fatigue,
- pain in extremities, and
- rash
What Are Possible Side Effects of Rubraca?
Common side effects of Rubraca include:
- nausea,
- fatigue (including weakness),
- vomiting,
- anemia,
- abdominal pain,
- changes in taste,
- constipation,
- decreased appetite,
- diarrhea,
- low levels of platelets in the blood (thrombocytopenia),
- shortness of breath,
- dizziness,
- low levels of while blood cells (neutropenia),
- rash,
- fever,
- skin sensitivity to sunlight, and
- itching.
What Is Nubeqa?
Nubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
What Is Rubraca?
Rubraca (rucaparib tablets) is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Patients are selected for therapy based on an FDA-approved companion diagnostic for Rubraca.
What Drugs Interact With Nubeqa?
Nubeqa may interact with rifampicin, itraconazole, midazolam, and rosuvastatin. Tell your doctor all medications and supplements you use.
What Drugs Interact With Rubraca?
Rubraca may interact with other drugs. Tell your doctor all medications and supplements you use.
How Should Nubeqa be Taken?
The dose of Nubeqa is 600 mg, (two 300 mg tablets) administered orally twice daily with food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.